Biosimilars Development Should Target “Residual Uncertainty,” FDA Says
Executive Summary
Agency officials stress their willingness to work with applicants, while an industry expert urges comparative testing in the setting or settings most sensitive to potential differences.
You may also be interested in...
Three Largest U.S. Generic Firms See Diversification As Best Path Through Reverse Patent Cliff
Expanded technological capabilities, narrowed focus on alternative dosage forms and harder-to-replicate products, and growing international reach are among the strategies being employed by Teva, Mylan and Watson in the face of 2013’s anticipated reverse patent cliff.
Korea’s Celltrion Expects Price Of Remsima Biosimilar To Be 70% Of Remicade
Celltrion expects Korea’s National Health Insurance to cover Remsima and to start sales in the third quarter.
Korea’s Celltrion Expects Price Of Remsima Biosimilar To Be 70% Of Remicade
Celltrion expects Korea’s National Health Insurance to cover Remsima and to start sales in the third quarter.